A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 51, Issue 1, 2012, Pages

  Wilens, Timothy E ^a   Bukstein, Oscar ^b   Brams, Matthew ^c   Cutler, Andrew J ^d   Childress, Ann ^e   Rugino, Thomas ^f   Lyne, Andrew ^g   Grannis, Kara ^h   Youcha, Sharon ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Bayou City Research   (United States)

^d Florida Clinical Research Center LLC   (United States)

^e Center for Psychiatry and Behavioral Medicine   (United States)

^f Children's Specialized Hospital   (United States)

^g Shire Pharmaceuticals   (United Kingdom)

^h SHIRE   (United States)

Author keywords

Attention deficit hyperactivity disorder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; GUANFACINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED RELEASE FORMULATION; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION;

EID: 83955162232     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2011.10.012     Document Type: Article

References (41)

1. R.C. Kessler, P. Berglund, O. Demler, R. Jin, K.R. Merikangas, E.E. Walters Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 2005 593 602
2. G. Polanczyk, M.S. de Lima, B.L. Horta, J. Biederman, L.A. Rohde The worldwide prevalence of ADHD: a systematic review and metaregression analysis Am J Psychiatry 164 2007 942 948
3. K.R. Merikangas, J.P. He, M. Burstein Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey ReplicationAdolescent Supplement (NCS-A) J Am Acad Child Adolesc Psychiatry 49 2010 980 989
4. S. Pliszka AACAP Work Group on Quality Issues Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
5. T.E. Wilens, J. Biederman, S. Brown Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD J Am Acad Child Adolesc Psychiatry 41 2002 262 268
6. S.R. Pliszka, M.L. Crismon, C.W. Hughes Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 45 2006 642 657
7. D.E. May, C.J. Kratochvil Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy Drugs 70 2010 15 40
8. Intuniv [package insert] 2011 Shire Pharmaceuticals Inc. Wayne, PA
9. Kapvay [package insert] 2010 Shionogi Pharma, Inc. Atlanta, GA
10. S.V. Faraone, M. Pucci, D. Coghill Pharmacotherapy for attention-deficit-hyperactivity disorder US Psychiatry Rev 2 2009 17 27
11. L.L. Greenhill, S. Pliszka, M.K. Dulcan Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults J Am Acad Child Adolesc Psychiatry 41 2 Suppl 2002 26S 49S
12. D.P. Cantwell Attention deficit disorder: a review of the past 10 years J Am Acad Child Adolesc Psychiatry 35 1996 978 987
13. L. Scahill, P.B. Chappell, Y.S. Kim A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder Am J Psychiatry 158 2001 1067 1074
14. T.E. Wilens, T. Spencer, J. Biederman, J. Wozniak, D. Connor Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology J Am Acad Child Adolesc Psychiatry 34 1995 110 112
15. J.M. Swanson, H.C. Kraemer, S.P. Hinshaw Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment J Am Acad Child Adolesc Psychiatry 40 2001 168 179
16. M. Steele, P.S. Jensen, D.M.P. Quinn Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 28 2006 1892 1908
17. M.D. Rapport, C. Denney, G.J. DuPaul, M.J. Gardner Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children J Am Acad Child Adolesc Psychiatry 33 1994 882 893
18. J. Biederman, E. Mick, S.V. Faraone Normalized functioning in youths with persistent attention-deficit/hyperactivity disorder J Pediatr 133 1998 544 551
19. J.K. Buitelaar, T.E. Wilens, S. Zhang, Y. Ning, P.D. Feldman Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo J Child Psychol Psychiatry 50 2009 335 342
20. C.W. Popper Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death J Child Adolesc Psychopharmacol 5 1995 157 166
21. G.M. Pohl, D.L. Van Brunt, W. Ye, W.W. Stoops, J.A. Johnston A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD) BMC Health Serv Res 9 2009 95
22. F.R. Sallee The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder Postgrad Med 122 2010 78 87
23. P.L. Hazell, J.E. Stuart A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children J Am Acad Child Adolesc Psychiatry 42 2003 886 894
24. D.R. Palumbo, F.R. Sallee, W.E. Pelham Jr, O.G. Bukstein, W.B. Daviss, M.P. McDermott CAT Study Team Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes J Am Acad Child Adolesc Psychiatry 47 2008 180 188
25. Tourette's Syndrome Study Group Treatment of ADHD in children with tics: a randomized controlled trial Neurology 58 2002 527 536
26. S.H. Kollins, R. Jain, M. Brams Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD Pediatrics 127 2011 e1406 e1413
27. J.M. Swanson, D. Flockhart, D. Udrea, D.P. Cantwell, D. Connor, L. Williams Clonidine in the treatment of ADHD: questions about safety and efficacy J Child Adolesc Psychopharmacol 5 1995 301 304
28. W.B. Daviss, N.C. Patel, A.S. Robb CAT Study Team Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis J Am Acad Child Adolesc Psychiatry 47 2008 189 198
29. J. Biederman, R.D. Melmed, A. Patel SPD503 Study Group A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder Pediatrics 121 2008 e73 e84
30. F. Sallee, J. McGough, T. Wigal, J. Donahue, A. Lyne, J. Biederman SPD503 Study Group Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry 48 2009 155 165
31. T.J. Spencer, M. Greenbaum, L.D. Ginsberg, W.R. Murphy Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder J Child Adolesc Psychopharmacol 19 2009 501 510
32. F.R. Sallee, A. Lyne, T. Wigal, J.J. McGough Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder J Child Adolesc Psychopharmacol 19 2009 215 226
33. G.J. DuPaul, T.J. Power, A.D. Anastopoulos, R. Reid ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation 1998 Guilford Press New York, NY
34. W. Guy Clinical global impressions ECDEU Assessment Manual for Psychopharmacology 1976 US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch Rockville, MD 218 222
35. T.E. Wilens, T.J. Spencer The stimulants revisited Child Adolesc Psychiatr Clin N Am 9 2000 573 603 viii
36. F.A. Lopez, C. White, J. Rubin Effects of guanfacine extended release on parent-reported behaviors in a randomized double-blind study of subjects with attention-deficit/hyperactivity disorder Poster presented at the American Professional Society of ADHD and Related Disorders November 5-6, 2010 Washington, DC
37. J. Rubin, F.A. Lopez, S. Youcha Impact of guanfacine extended release on cognitive problems and inattention Poster presented at the 2010 Annual Meeting of the Society for Developmental and Behavioral Pediatrics September 11-14, 2010 Boston, MA
38. P.A. Ahmann, S.J. Waltonen, K.A. Olson, F.W. Theye, A.J. Van Erem, R.J. LaPlant Placebo-controlled evaluation of Ritalin side effects Pediatrics 91 1993 1101 1106
39. J. Biederman, S. Krishnan, Y. Zhang, J.J. McGough, R.L. Findling Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study Clin Ther 29 2007 450 463
40. R.L. Findling, A.C. Childress, A.J. Cutler Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 50 2011 395 405
41. P.A. Ahmann, F.W. Theye, R. Berg, A.J. Linquist, A.J. Van Erem, L.R. Campbell Placebo-controlled evaluation of amphetamine mixturedextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects Pediatrics 107 2001 E10